ErbB family targeting

Jennifer D Black, Michael G Brattain, Smitha A. Krishnamurthi, Dawn M. Dawson, James K.V. Willson

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Drugs for specific molecular targets have generated a great deal of excitement for their potential in cancer treatment, particularly with respect to our molecular understanding of cancer in recent years. The clinical utility of antibodies and small molecule kinase inhibitors has been demonstrated. The ErbB family of receptors is at the forefront of targets that are the subject of clinical trials. However, the activities of epidermal growth factor receptor antagonists have not been impressive as single agents. One of the lessons learned with this class of targets is that we currently do not know how to optimally apply them to the treatment of cancer. This review will discuss the issues contributing to this situation and the approaches that are currently being launched to resolve these issues.

Original languageEnglish (US)
Pages (from-to)1451-1454
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume4
Issue number12
StatePublished - Dec 1 2003

Fingerprint

Neoplasms
Epidermal Growth Factor Receptor
Phosphotransferases
Clinical Trials
Antibodies
Pharmaceutical Preparations
ErbB Receptors

Keywords

  • Epidermal growth factor receptor
  • ErbB-2
  • Identification of patient subsets
  • Molecular targeting
  • Signal transduction profiling

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Black, J. D., Brattain, M. G., Krishnamurthi, S. A., Dawson, D. M., & Willson, J. K. V. (2003). ErbB family targeting. Current Opinion in Investigational Drugs, 4(12), 1451-1454.

ErbB family targeting. / Black, Jennifer D; Brattain, Michael G; Krishnamurthi, Smitha A.; Dawson, Dawn M.; Willson, James K.V.

In: Current Opinion in Investigational Drugs, Vol. 4, No. 12, 01.12.2003, p. 1451-1454.

Research output: Contribution to journalReview article

Black, JD, Brattain, MG, Krishnamurthi, SA, Dawson, DM & Willson, JKV 2003, 'ErbB family targeting', Current Opinion in Investigational Drugs, vol. 4, no. 12, pp. 1451-1454.
Black JD, Brattain MG, Krishnamurthi SA, Dawson DM, Willson JKV. ErbB family targeting. Current Opinion in Investigational Drugs. 2003 Dec 1;4(12):1451-1454.
Black, Jennifer D ; Brattain, Michael G ; Krishnamurthi, Smitha A. ; Dawson, Dawn M. ; Willson, James K.V. / ErbB family targeting. In: Current Opinion in Investigational Drugs. 2003 ; Vol. 4, No. 12. pp. 1451-1454.
@article{f53ab886611a41dd81d1595bac621f0f,
title = "ErbB family targeting",
abstract = "Drugs for specific molecular targets have generated a great deal of excitement for their potential in cancer treatment, particularly with respect to our molecular understanding of cancer in recent years. The clinical utility of antibodies and small molecule kinase inhibitors has been demonstrated. The ErbB family of receptors is at the forefront of targets that are the subject of clinical trials. However, the activities of epidermal growth factor receptor antagonists have not been impressive as single agents. One of the lessons learned with this class of targets is that we currently do not know how to optimally apply them to the treatment of cancer. This review will discuss the issues contributing to this situation and the approaches that are currently being launched to resolve these issues.",
keywords = "Epidermal growth factor receptor, ErbB-2, Identification of patient subsets, Molecular targeting, Signal transduction profiling",
author = "Black, {Jennifer D} and Brattain, {Michael G} and Krishnamurthi, {Smitha A.} and Dawson, {Dawn M.} and Willson, {James K.V.}",
year = "2003",
month = "12",
day = "1",
language = "English (US)",
volume = "4",
pages = "1451--1454",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "12",

}

TY - JOUR

T1 - ErbB family targeting

AU - Black, Jennifer D

AU - Brattain, Michael G

AU - Krishnamurthi, Smitha A.

AU - Dawson, Dawn M.

AU - Willson, James K.V.

PY - 2003/12/1

Y1 - 2003/12/1

N2 - Drugs for specific molecular targets have generated a great deal of excitement for their potential in cancer treatment, particularly with respect to our molecular understanding of cancer in recent years. The clinical utility of antibodies and small molecule kinase inhibitors has been demonstrated. The ErbB family of receptors is at the forefront of targets that are the subject of clinical trials. However, the activities of epidermal growth factor receptor antagonists have not been impressive as single agents. One of the lessons learned with this class of targets is that we currently do not know how to optimally apply them to the treatment of cancer. This review will discuss the issues contributing to this situation and the approaches that are currently being launched to resolve these issues.

AB - Drugs for specific molecular targets have generated a great deal of excitement for their potential in cancer treatment, particularly with respect to our molecular understanding of cancer in recent years. The clinical utility of antibodies and small molecule kinase inhibitors has been demonstrated. The ErbB family of receptors is at the forefront of targets that are the subject of clinical trials. However, the activities of epidermal growth factor receptor antagonists have not been impressive as single agents. One of the lessons learned with this class of targets is that we currently do not know how to optimally apply them to the treatment of cancer. This review will discuss the issues contributing to this situation and the approaches that are currently being launched to resolve these issues.

KW - Epidermal growth factor receptor

KW - ErbB-2

KW - Identification of patient subsets

KW - Molecular targeting

KW - Signal transduction profiling

UR - http://www.scopus.com/inward/record.url?scp=1642475098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642475098&partnerID=8YFLogxK

M3 - Review article

VL - 4

SP - 1451

EP - 1454

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 12

ER -